Two satchachewan women are champions of new medical devices, they say not only lowers the rate of infections in intravenous catheter users, but also kills superbugs, which do not respond to antibiotic treatments.
Chainlock – Originally developed by Microbiologist Peter Kate – is not a drug. It is a non-antibiotic, antimicrobial solution that is an anticoagulant and disinfectant. When the solution is included in the catheter, it breaks down and defends against blood clot blockages and kills bacteria causing infections.
It also helps to break down and stop the growth of biofilm – a slime barrier created by unwanted bacteria to protect itself.
"Specifically for high-risk patients who need long-term catheters, one of four – if they get an infection through this catheter – will die from that infection, not from their disease," said Humboldt's native Karen Muller, CEO of Sterile Care. The company creates the resource for the worldwide marketplace.
"This launch which is supposed to save their lives could also take it away."
Hospitals use saline solution or heparin to clear catheter lines. That works to break down clots, but "nothing at all" to stop the growth of bacteria, says SterileCare's chief scientific clerk, Chantal Linesse, who works out of her home office just outside Saskatoon.
For patients using long-term catheters in situations such as chemotherapy or dialysis, if bacteria do take forming in the line, the next time they receive treatment it makes its way into the bloodstream, leaving the immune system immune to the disease and both. An infection.
Lainesse said KiteLock could be a step in the World Health Organization's global mandates to find new solutions that kill bacteria without antibiotics, to better protect against antibiotic resistant superbugs – which the United Nations calls a "global health emergency."
"We have tried this in Canadian hospitals and all of the germs in these patients have tested the germs against our product and have killed all the superbugs including biofilms," he said.
Canada is the first country in the world to use Health Canada approved by Health Canada in May 2016.
For those little patients already using the device, the results are undeniable, mailer said.
"One of those stories is about a 10-year-old who has a central line for her. She's chronic, so she has (the catheter) for life. She used to go to emergency once or twice a month, she Would have missed school and it was either for an infection or a blockage in the line, but since she was on our product for over a year, she wasn't in the emergency once.
Lainesse and Mueller have new innovations in the medical field can take two to five years to make it through the procurement process and prove clinical and financial advantages.
The device is more expensive than the current options available, but once a patient develops an infection through their catheter, it costs around $ 15,000 to treat the infection – which is about the same amount it would cost a patient to use Chainlock for eight years, Muller Said.
"It's a game changer … and we're just trying to get it out there. If you think of Penicillin and it took a long time for Penicillin to finally make its mark … our product is compared to scientific groups like The next penicillin.